Literature DB >> 16565361

Ubiquitin-conjugating enzyme 3 delays human lens epithelial cells in metaphase.

Qing Liu1, Fu Shang, Elizabeth Whitcomb, Weimin Guo, Wei Li, Allen Taylor.   

Abstract

PURPOSE: Ubc3/Cdc34 is a ubiquitin-conjugating enzyme (Ubc) with well established functions in the G1-to-S-phase transition. Expecting to find similar effects in human lens epithelial cells (HLECs), the authors explored roles for this ubiquitin-conjugating enzyme in regulation of the HLEC cycle.
METHODS: Catalytically incompetent Ubc3 (C88S, L97S), wild-type (wt)Ubc3, and mutant (mt)Ubc2 (C93A) were expressed in HLECs, by using an adenoviral vector, and cell cycle progression was assessed.
RESULTS: Expression of mt- and wtUbc3, but not empty virus or mtUbc2, delayed the cell cycle in metaphase, rather than the expected G1 phase. Expression of both Ubc3s also stabilized M-phase regulators, cyclin A, cyclin B, and securin. Thus, it appeared that the Ubc3 enzymes were playing roles different from canonical proteolytic functions in targeting G1/S regulators for degradation. We also directly investigated the effect of inhibiting the proteasome on the cell cycle of HLECs. When the proteasome inhibitor was added to S-phase cells, the M-phase regulators were stabilized, and the cells were arrested in the G2/M phase. In contrast, if the proteasome inhibitor was added before the cells entered the S phase, stabilization of the G1 kinase inhibitors p21WAF and p27KIP was observed and the cells were arrested in the G1 phase.
CONCLUSIONS: The ubiquitin-proteasome pathway is involved in regulation of transitions between all phases of the HLEC cycle. However, in contrast with previously described roles for Ubc3 in governing G1/S transitions, expression of Ubc3 delays the HLEC cycle in metaphase. The data suggest novel roles for Ubc3 that do not involve the transfer of ubiquitin in the M phase in the HLEC cell cycle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565361     DOI: 10.1167/iovs.05-0935

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Novel control of S phase of the cell cycle by ubiquitin-conjugating enzyme H7.

Authors:  Elizabeth A Whitcomb; Edward J Dudek; Qing Liu; Allen Taylor
Journal:  Mol Biol Cell       Date:  2008-10-22       Impact factor: 4.138

2.  Stabilization of p27Kip1/CDKN1B by UBCH7/UBE2L3 catalyzed ubiquitinylation: a new paradigm in cell-cycle control.

Authors:  Elizabeth A Whitcomb; Yien Che Tsai; Johnvesly Basappa; Ke Liu; Aurélie K Le Feuvre; Allan M Weissman; Allen Taylor
Journal:  FASEB J       Date:  2018-08-16       Impact factor: 5.191

3.  SCF E3-mediated autoubiquitination negatively regulates activity of Cdc34 E2 but plays a nonessential role in the catalytic cycle in vitro and in vivo.

Authors:  K Matthew Scaglione; Parmil K Bansal; Andrew E Deffenbaugh; Alexi Kiss; Johnnie M Moore; Sergey Korolev; Ross Cocklin; Mark Goebl; Katsumi Kitagawa; Dorota Skowyra
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

4.  The loop-less tmCdc34 E2 mutant defective in polyubiquitination in vitro and in vivo supports yeast growth in a manner dependent on Ubp14 and Cka2.

Authors:  Agnieszka Lass; Ross Cocklin; Kenneth M Scaglione; Michael Skowyra; Sergey Korolev; Mark Goebl; Dorota Skowyra
Journal:  Cell Div       Date:  2011-03-31       Impact factor: 5.130

5.  Newborn mouse lens proteome and its alteration by lysine 6 mutant ubiquitin.

Authors:  Fu Shang; Phillip A Wilmarth; Min-lee Chang; Ke Liu; Larry L David; Maria Andrea Caceres; Eric Wawrousek; Allen Taylor
Journal:  J Proteome Res       Date:  2014-02-21       Impact factor: 4.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.